Eisai has added to its genomics capabilities. The latest move sees the Japanese drugmaker's nascent Integrated Human Genomics (IHGx) Research Unit team up with Genomics plc, an Oxford University spinout founded in response to the United Kingdom's 100,000 Genomes Project.
Researchers at the University of Michigan are trying to speed toward their goal of enrolling 20,000 people in a study by piggybacking onto Facebook's vast social network. And the genotypic and phenotypic data gathering project is off to a brisk start, with more than 2,000 people signing up in the days after its public launch.
Genome Canada is aiming to retool the country's genomics infrastructure by plowing $12.2 million in federal funding and a similar amount from other sources into 10 research centers.
The 100,000 Genomes Project is up and running in the United Kingdom. And with the population-scale sequencing drive having already made breakthroughs in identifying rare diseases, Genomics England has handed out $12 million to bolster its data analysis capabilities.
RainDance Technologies has taken a step toward completing its long-planned IPO by filing the paperwork for a $60 million offering.
Foundation Medicine has followed up its transformational deal with Roche by inking an oncology alliance with Eisai-backed H3 Biomedicine. The deal sees Foundation Medicine pair its genomic database with H3's computational biology capabilities.
The Financial Times has taken a look inside Chinese sequencing giant BGI and the implications of its mission to sequence the genomes of one million humans, one million microorganisms and one million plants and animals.
Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.